Mortality/major ischemic events at 90 days were no lower than with a restrictive strategy—but cardiac complications differed.

The device may help boost early detection of HFrEF for people living in low-resource settings where echo is scarce.

With such a large reduction, coupled with general skepticism around PUFAs, experts would like to see the trial replicated.

An oral agent is needed because some patients don’t like injectables, and some doctors don’t prescribe them, experts say.

DES, adding clopidogrel in the chronic phase of coronary disease had no ischemic benefit and increased bleeding.

The noninferiority trial of patients at risk for both bleeding and stroke, in a surprise turn, found standard care to be ...

OCEAN, said Albert, provides important risk-benefit data that doctors can now use in discussions with their patients. For ...

The approach is “very exciting,” but one expert says a lot more research is needed, especially around safety, before clinical ...

NEW ORLEANS, LA—Among patients with atrial fibrillation (AF) undergoing PCI, 1 month of dual therapy with a direct oral ...

It’s the first study to show a PCSK9 inhibitor can reduce major events in high-risk patients who haven’t yet had one.

The drug, given as a weekly subcutaneous injection, reduced both triglycerides and liver fat in the phase II trial.

Experts gathered at the TCT MedTech Innovation Forum to discuss successes, failures, barriers, and solutions in healthcare.